EVALUATION OF NEW TREATMENTS:

THE SWITCH TO ABIRATERONA +

DEXAMETASONA
Authors: Encarnación Navarro JA, Sánchez Pérez M, Laborda Segovia A, De la Fuente Muñoz I, López Soler
FJ, Lozano Martínez AJ, Cárdenas Cánovas E, Romero Borque MA, Rodríguez Sánchez SP, Padilla De la
Fuente D, García Fernández R, Manso Murcia C, Otálora Valderrama S, Ortega Martín I, Moreno Cano R.

Hospital: Virgen de la Arrixaca Clinical University Hospital.

Introduction and objectives:

Assess the effects of the switch from prednisone to dexamethasone due to progression of PSA in a patient with castration-
resistant prostate cancer treated with abiraterone acetate (AA).

Material and methods: October/18 increase of PSA:

Appearance of ascites. In July/17 clinical, radiological and 25.58 ng/ml, the patient was
Cytology + for adenocarcinoma. serological progression with PSA 97 asymptomatic. We decide to
Analytical tests showed PSA of ng/ml. Initiates AA + Prednisone (10 switch to AA dexamethasone
104 ng/ml mg) on 07/01/2017. 0.5 mg.

In December/15 we initiate
Diagnosis in 2010 of T2bNOMO PET CT in February/18 without
treatment with docetaxel, with
prostate adenocarcinoma treated evidence of macroscopic malignant
biochemical response, producing
with RT and BAC disease.
2010 2015 nadir PSA of 29 ng/ml in July/16.
2015 207 2018 2018
Results:
Initiation AA + Fortecortín Initiation AA + Prednisone

Initiation AA + Dexamethasone

Figure 1. Evolution of PSA after switch from abiraterone + prednisone to abiraterone + fortecortin Figure 2..Evolution of the patient's PSA since biochemical relapse in 2015 and initiation of docetaxel.

Conclusions:
Switching treatment from prednisone to dexamethasone seems to be a safe and inexpensive way to obtain an increase in progression-free survival
for patients being treated with AA treatment.
No liver toxicity (liver enzymes <32 U/L) or high bilirubin levels (<0.73 mg/dl) suggestive of liver damage, or alteration of potassium levels was
observed in this patient.

14--P Oncología radioterápica. Cáncer de próstata avanzado

Colaboración limitada a la impresión,
7AORo

gestión y acceso on-line de los posters, sin

derivarse responsabilidad alguna sobre los

Juan Antonio Encarnación DOI: 10.3252/pso.es.7aor.2019

contenidos u opiniones vertidos en ellos
por sus autores.